Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
XTalks
AUGUST 17, 2020
Cue Biopharma’s first molecule, for head and neck cancer, contains a peptide from the E7 protein of the human papillomavirus (HPV), which is a key protein in HPV-induced epithelial cancers, particularly head and neck cancer. Targeting HPV-Induced Head and Neck Cancer. The T cell epitope is usually an 8 – 10 amino acid peptide.
98 
Let's personalize your content